Transfection-independent production of alphavirus replicon particles based on poxvirus expression vectors.
This report describes a transfection-independent system for packaging alphavirus replicon vectors using modified vaccinia virus Ankara (MVA) vectors to express all of the RNA components necessary for the production of Venezuelan equine encephalitis (VEE) virus replicon particles (VRP). Infection of mammalian cells with these recombinant MVA vectors resulted in robust expression of VEE structural genes, replication of the alphavirus vector and high titers of VRP. In addition, VRP packaging was achieved in a cell type (fetal rhesus lung) that has been approved for the manufacturing of vaccines destined for human use.
Vasilakis
Nikos
N
Viral Vaccine Discovery, Wyeth Vaccines Research, Pearl River, New York 10965, USA.
Falvey
Darlene
D
Gangolli
Seema S
SS
Coleman
John
J
Kowalski
Jacek
J
Udem
Stephen A
SA
Zamb
Timothy J
TJ
Kovacs
Gerald R
GR
D000524:Alphavirus / Q000235:genetics; D004279:DNA, Viral / Q000008:administration & dosage* / Q000235:genetics*; D016503:Drug Delivery Systems / Q000379:methods*; D004666:Encephalitis Virus, Venezuelan Equine / Q000235:genetics*; D015967:Gene Expression Regulation, Viral; D018014:Gene Transfer Techniques; D005822:Genetic Vectors; D012093:Replicon / Q000235:genetics*; D014162:Transfection / Q000379:methods*; D014616:Vaccinia virus / Q000235:genetics*; D014771:Virion / Q000235:genetics*
D004279:DNA, Viral